Anti-CEA-CAR-T-cell-therapy-TNK-Therapeutics

Drug Profile

Anti-CEA-CAR-T-cell-therapy-TNK-Therapeutics

Alternative Names: Anti-CEA CAR-T; Anti-CEA T-cells; CAR-T CEA; CAR-T-CEA-therapy; CEA CART; Designer T-cells

Latest Information Update: 12 Apr 2017

Price : $50

At a glance

  • Originator BDL Products, Inc.; CARgenix Holdings LLC
  • Developer Roger Williams Medical Center
  • Class CAR-T cell therapies
  • Mechanism of Action Carcinoembryonic antigen inhibitors; Cytotoxic T lymphocyte stimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Liver metastases

Most Recent Events

  • 03 Apr 2017 Safety and efficacy results from the phase I HITM-SIR clinical trial in Liver metastases released by Sorrento Therapeutics
  • 03 Apr 2017 TNK Therapeutics in collaboration with Roger Williams Cancer Center plans a phase II trial for Liver metastases in USA
  • 01 Feb 2017 The Roger Williams Medical Center in collaboration with the University of Colorado initiates the phase-I HITM-SURE clinical trial in Liver metastases (Second-line or greater therapy, Inoperable/Unresectable) in USA (Intrahepatic) (NCT02850536)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top